RESUMO
BACKGROUND: Desidustat (DES) belongs to a new category of drugs, i.e., Hypoxia-Inducible Factor (HIF) propyl hydroxylase inhibitor, and is used for the treatment of anemia in chronic kidney disease. However, no method has yet been reported in the literature for the estimation of drugs. OBJECTIVE: The objective of the study is to develop a simple, precise, and accurate method for determining DES in bulk and pharmaceutical dose form. METHODS: The physicochemical characterization of the drug was performed using methanol as a solvent to establish the identity. According to ICH Q2 criteria, validation characteristics, such as specificity, linearity, accuracy, precision, limits of detection and quantification, and robustness, were assessed. RESULTS: Maximum absorbance wavelength was observed at 229 nm. The sample solution remained stable for up to 12 hours. The linear response from 2 to 12 µg/ml of DES was y = 0.1087x + 0.0962 and r2 = 0.9963. The accuracy was between 100 to 101%. Precision was recorded under three criteria: repeatability, intraday and interday, for which results fell within the acceptable ranges (<2%). The limit of detection (LOD) and limit of quantification (LOQ) of the technique were 0.434 µg/ml and 1.316 µg/ml, respectively. CONCLUSION: The proposed method was found to be beneficial for drug monitoring and the ongoing analysis of DES in research and quality control laboratories. This approach is simple, precise, rapid, economical, and sensitive.
